Results 1 to 10 of about 19,861 (100)

KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?

Cells, 2022
Background: KRAS G12D mutation subtype is present in over 40% of pancreatic ductal adenocarcinoma (PDAC), one of the leading global causes of cancer death.
Henry Shen, Joanne Lundy, Andrew H. Strickland, Marion Harris, Michael Swan, Christopher Desmond, Brendan J. Jenkins, Daniel Croagh   +7 more
doaj   +1 more source

Use of DNA‐alkylating pyrrole‐imidazole polyamides for anti‐cancer drug sensitivity screening in pancreatic ductal adenocarcinoma

Cancer Medicine, 2023
Background Activating mutations of the KRAS occurs in >90% of pancreatic ductal adenocarcinoma (PDAC) cases. However, direct pharmacological targeting of the activated KRAS protein has been challenging.
Akiko Tsujimoto, Niina Matsuo, Xiaoyi Lai, Takahiro Inoue, Hiroyuki Yoda, Jason Lin, Yoshinao Shinozaki, Takayoshi Watanabe, Nobuko Koshikawa, Atsushi Takatori, Hiroki Nagase   +10 more
doaj   +1 more source

Somatic mutation analysis of Mesonephric-Like adenocarcinoma and associated putative precursor Lesions: Insight into pathogenesis and potential molecular treatment targets

Gynecologic Oncology Reports, 2022
Aims: Mesonephric-like adenocarcinoma (MLA) is a recently described histologic tumor subtype of the Müllerian tract. MLA can arise in association with Müllerian lesions that share common mutations.
Elizabeth Arslanian, Kamaljeet Singh, C. James Sung, M. Ruhul Quddus   +3 more
doaj   +1 more source

The current understanding of KRAS protein structure and dynamics

Computational and Structural Biotechnology Journal, 2020
One of the most common drivers in human cancer is the mutant KRAS protein. Not so long ago KRAS was considered as an undruggable oncoprotein. After a long struggle, however, we finally see some light at the end of the tunnel as promising KRAS targeted ...
Tatu Pantsar
doaj   +1 more source

Correlation of miR-31 and miR-373 expression with KRAS mutations and its impact on prognosis in colorectal cancer

Journal of the Egyptian National Cancer Institute, 2022
Introduction Colorectal cancers (CRC) are among the most common cancers. There are different modalities for treatment including chemotherapy, surgery, and radiotherapy.
Hasan Ashoori, Shaghayegh Kamian, Farnaz Vahidian, Mohammad Ebrahim Ghamarchehreh   +3 more
doaj   +1 more source

Fitness of unregulated human Ras mutants modeled by implementing computational mutagenesis and machine learning techniques

Heliyon, 2019
Ras proteins play a pivotal role as oncogenes by participating in diverse signaling events, including those linked to cell growth, differentiation, and proliferation.
Majid Masso, Arnav Bansal, Preethi Prem, Akhil Gajjala, Iosif I. Vaisman   +4 more
doaj   +1 more source

Role and mechanism of action of nuclear receptor coactivator 4 in the development of acquired resis-tance to targeted inhibitors in pancreatic cancer with KRAS G12C mutation [PDF]

精准医学杂志
Objective To investigate the role and mechanism of action of nuclear receptor coactivator 4 (NCOA4) in acquired resistance to targeted inhibitors in pancreatic cancer with KRAS G12C mutation.
CHANG Hao, WANG Ya'nan, LIU Shihai, WANG Jing
doaj   +1 more source

Unraveling the Interplay of KRAS, NRAS, BRAF, and Micro-Satellite Instability in Non-Metastatic Colon Cancer: A Systematic Review

Diagnostics
Microsatellite Instability (MSI-H) occurs in approximately 15% of non-metastatic colon cancers, influencing patient outcomes positively compared to microsatellite stable (MSS) cancers. This systematic review focuses on the prognostic significance of KRAS,
Elena Orlandi, Mario Giuffrida, Serena Trubini, Enrico Luzietti, Massimo Ambroggi, Elisa Anselmi, Patrizio Capelli, Andrea Romboli   +7 more
doaj   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Clonally Related Chronic Myelomonocytic Leukemia and Erdheim-Chester Disease with KRAS Mutation: A Rare and Challenging Case

Acta Médica Portuguesa
n/a.
Tiago Monteiro-Brás, Inês Araújo, Maria Luís Amorim, Alexandra Azevedo, Luísa Regadas, Raquel Faria, Rita Coutinho   +6 more
doaj   +1 more source